Table 1

Subject demographics

All women (n = 85)Tamoxifen (n = 39)Observation (n = 46)P*
Mean (Range)Mean (Range)Mean (Range)
Age (y)50 (33-64)51 (42-63)49 (33-64)0.10
5-y risk estimate3.0 (0.6-6.9)3.1 (1.7-6.9)3.0 (0.6-5.6)0.64
n (%)n (%)n (%)P
Cancer diagnosis
 DCIS6 (7)5 (13)1 (2)0.09
 Invasive9 (11)5 (13)4 (9)0.73
Race
 White69 (81)35 (90)34 (74)0.09
 Other16 (19)4 (10)12 (26)
Menopausal status (b/6)§
 Pre/pre32 (38)10 (26)22 (48)0.04
 Post/post41 (48)19 (49)22 (48)0.99
 Pre/post12 (14)10 (26)2 (4)0.01
Median (mean)Median (mean)Median (mean)P
Biomarker
 ER24.59 (25.26)27.98 (29.23)19.88 (21.88)0.002
 Ki670.11 (0.59)0.32 (0.57)0.11 (0.50)0.30
 Cox240.00 (42.43)46.15 (44.97)36.64 (38.14)0.10
Baseline
 No. lavaged ducts per woman
  All3.0 (2.98)2.0 (2.72)3.0 (3.2)0.05
  Cell counts ≥1002.0 (2.46)2.0 (2.44)2.0 (2.48)0.47
Biomarker
 ER22.17 (22.88)23.86 (24.25)20.14 (21.43)0.18
 Ki670.00 (0.31)0.00 (0.20)0.08 (0.42)0.25
 Cox238.91 (39.25)35.09 (38.88)31.67 (35.51)0.71
6 mo
 Median lavaged ducts per woman
  All3.0 (3.04)3.0 (2.92)3.0 (3.13)0.23
  Cell counts ≥ 1002.0 (2.29)2.0 (2.18)2.0 (2.39)0.13
  • *P value from two-sided independent sample t test.

  • P value from two-sided Fisher's exact test.

  • T1a/b carcinoma in contralateral breast.

  • §Self-reported at baseline (b) and 6 mo (6) DL.

  • P value from Wilcoxon signed-rank test.